

Confirmation of Efficacy

CELLIGENT® 2020

Page 1 of 2

We herewith confirm that the change in the formulation of CELLIGENT® did not alter the efficacy of the product.

A study with 10 participants subjected to UVB irradiation with a dose of 1.4 - 1.5 over the individual minimal erythmal dose (MED) revealed no difference between the former formulation (INCI: Helianthus Annuus Seed Oil, Ethyl Ferulate, Polyglyceryl-5 Trioleate, Rosmarinus Officinalis Leaf Extract, Aqua, Disodium Uridine Phosphate, Tocopherol) and the new formulation (INCI: Helianthus Annuus Seed Oil, Ethyl Ferulate, Rosmarinus Officinalis Leaf Extract, Tocopherol).

Both formulations accelerated the recovery of the erythema in the same way as compared to the untreated condition (Figure 1).

The omitted Disodium Uridine Phosphate did not contribute significantly to protect the skin from UV radiation. The experiments on 3D skin models showing the protective measure of CELLIGENT® in respect to tissue destruction or DNA damage let us therefore conclude, that the mode of action is not affected. No thymidine dimers were induced when CELLIGENT® was present and as such, Disodium Uridine Phosphate is not essential for CELLIGENT® to take effect. As such, all reported *in-vitro* and *in-vivo* experiments can be transferred to the new formulation without any restrictions.




Figure 1: Reduction of UVB-induced erythema. No difference in the recovery from UVB-induced erythema was observed for both tested CELLIGENT® formulations *in-vivo*. The new formulation tended even to a higher efficacy.

Disclaimer

Utilisation of this document or parts thereof as well as product names for commercial or industrial applications is subject to explicit written approval by RAHN AG. This information is based on our own experience to date and we believe it to be reliable. It is intended only as a guide to use at your discretion and risk. We cannot guarantee favourable results and we assume no liability in connection with its use, or the use of the methods or products described. None of this information is to be taken as a license to operate under, or a recommendation to infringe, patents.

Version: 08/2018

Confirmation of Efficacy

CELLIGENT® 2020

Page 2 of 2

The original study report is available after signing a Non-Disclosure Agreement.

Stefan Hettwer, Senior R&D Manager Cosmetic Actives



RAHN AG
Dörflistrasse 120
CH-8050 Zürich
www.rahngroup.com

Zurich

14-Aug-2018

Disclaimer

Utilisation of this document or parts thereof as well as product names for commercial or industrial applications is subject to explicit written approval by RAHN AG. This information is based on our own experience to date and we believe it to be reliable. It is intended only as a guide to use at your discretion and risk. We cannot guarantee favourable results and we assume no liability in connection with its use, or the use of the methods or products described. None of this information is to be taken as a license to operate under, or a recommendation to infringe, patents.

Version: 08/2018